Meissa Vaccines: Marty Moore, Founder And Chief Executive Officer
Meissa Vaccines is a pharmaceutical start-up company focused on advancement of unmet vaccines against viruses that cause serious human diseases, such as respiratory syncytial
BioGraph 55, Inc: Paul Tumeh, Co-founder and CEO
BioGraph 55, Inc. is a San Francisco based early-stage target discovery and drug development biotech company focused on immuno-oncology. The company leverages a proprietary and scientifically validated (through external partners) spatial-mapping technology platform called SPARTA (Spatial Processing And Regional Tissue Analysis) that collects biological information from cellular interactions in their native environment and integrates this information with genomic and transcriptomic data to identify new drug targets. The first program aims to develop an antibody therapy that i) targets refractory, “hot” solid tumors, ii) removes local immunosuppression from “hot” tumors and iii) uses a biomarker assay to identify patients likely to benefit from monotherapy.
Inflammatix: Tim Sweeney, CEO
Inflammatix is a molecular diagnostics company developing rapid tests that read the immune system to resolve major clinical and public health challenges. We are initially focused on developing tests for acute bacterial and viral infections, and sepsis based on patent-pending biomarkers exclusively licensed from Stanford University. Beyond this initial focus, our expert bioinformatics and assay development teams are poised to build a host response-based diagnostics pipeline that includes tests for tropical infections, autoimmune diseases, transplant rejection and other conditions.
SapVax, LLC is dedicated to the development and commercialization of a pipeline of powerful, self-adjuvanting peptide-based cancer vaccines. Our proprietary platform consists of highly specific and effective, novel TLR2 agonist adjuvants covalently conjugated to virtually any synthetic long peptide antigen. Our lead vaccine, SVX-ESO, targets the well-characterized tumor antigen, NY-ESO-1, and is in late stage preclinical development for ovarian cancer. Our second lead program is in discovery stage for the development of a personalized neoantigen cancer vaccine.
Angany is a privately-owned, pre-clinical pharmaceutical company whose goal is to bring a new generation of allergy products to the market. Angany uses a unique cGMP recombinant technology to produce pure individual allergens for in vivo diagnostic and complementary allergen biosynthetic nanoparticles for curative therapy. Angany’s allergen bioparticles are self-adjuvanted and have unique immunomodulatory characteristics that make them the first true therapeutic vaccine candidate of the allergy industry. These should represent a disruptive answer to the shortcomings of current allergenic extracts. Angany believes its nanoparticle platform will also find direct applications in cancer immunotherapy. Angany was first established in France in 2010 and later acquired by a Canadian entity. It currently has activities both in Val de Reuil (France) and Québec City (Canada).
Vaccines are the most cost-effective form of medicine ever developed. Yet, we chronically under invest in this most valuable form of medicine. To bridge this gap Verndari is integrating proprietary sutransformational technologies combining cutting edge vaccine design with cutting edge vaccine delivery. With the addition of adjuvant, this enables us to offer the complete package of vaccine antigen + adjuvant + delivery. Verndari is focused on influenza vaccine modernization. On September 19, 2019 President Trump announced a national initiative to modernize influenza vaccines. Verndari’s approach aligns very well with the Executive Order’s objectives and specifics.